Efficacy and safety of long-term treatment with lenalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma

Data from two randomized pivotal, phase 3 trials evaluating the combination of lenalidomide and dexamethasone in relapsed/refractory multiple myeloma (RRMM) were pooled to characterize the subset of patients who achieved long-term benefit of therapy (progression-free survival ⩾3 years). Patients wit...

Descripción completa

Detalles Bibliográficos
Autores principales: Dimopoulos, M A, Swern, A S, Li, J S, Hussein, M, Weiss, L, Nagarwala, Y, Baz, R
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2014
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4571985/
https://www.ncbi.nlm.nih.gov/pubmed/25382609
http://dx.doi.org/10.1038/bcj.2014.77

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4571985/
https://www.ncbi.nlm.nih.gov/pubmed/25382609
http://dx.doi.org/10.1038/bcj.2014.77

Ejemplares similares